TAPUR - Calfa, Carmen
-
Investigator:
Carmen Calfa
Email
Coordinator: Dina Caceres
+1 (305) 2437561
IRB: 20170529
SDG: Breast Cancer
Disease Site(s): Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
Sponsor: ASCO
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"
20200056 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator:
IRB: 20200056
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
Sponsor: DECIPHERA
Enrolling Sites:
Sylvester
Title: A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"
20201131 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator:
IRB: 20201131
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Multiple
Sponsor: DECIPHERA
Enrolling Sites:
Sylvester
Title: A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
Eligibility Criteria - NCT04530981 *This information has been extracted from " www.clinicaltrials.gov"
20201132 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator:
IRB: 20201132
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Soft Tissue
Sponsor: Tracon
Enrolling Sites:
Sylvester
Title: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy
Eligibility Criteria - NCT04480502 *This information has been extracted from " www.clinicaltrials.gov"
20211062 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator:
IRB: 20211062
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Multiple
Sponsor: Sumitomo Dainippon Pharma Oncology
Enrolling Sites:
Sylvester
Title: A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid Tumors
Eligibility Criteria - NCT03604783 *This information has been extracted from " www.clinicaltrials.gov"
20230466 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator:
IRB: 20230466
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bones and Joints,Soft Tissue
Sponsor: Alliance
Enrolling Sites:
Deerfield
Plantation
SylvesterTitle: A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
Eligibility Criteria - NCT05633381 *This information has been extracted from " www.clinicaltrials.gov"
20160793 - Dhir Aditi
-
Investigator:
Aditi Dhir
Email
Coordinator: Eva Pavicic
+1 (305) 2437846
IRB: 20160793
SDG: Pediatric Cancer
Disease Site(s): Soft Tissue
Sponsor: Moffitt Cancer Center
Enrolling Sites:
JMH
SylvesterTitle: Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Eligibility Criteria - NCT02945800 *This information has been extracted from " www.clinicaltrials.gov"
20221175 - Jonczak Emily
-
Investigator:
Emily Jonczak
Email
Coordinator:
IRB: 20221175
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bones and Joints
Sponsor: AmMax Bio. Inc
Enrolling Sites:
Sylvester
Title: A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra articular AMB-05X Injections in Subjects with Tenosynovial Giant Cell Tumor
Eligibility Criteria - NCT05349643 *This information has been extracted from " www.clinicaltrials.gov"
20191009 - Pimentel Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator:
IRB: 20191009
SDG: Pancreatic, Liver, and Related Cancers
Disease Site(s): Bones and Joints,Lip, Oral Cavity and Pharynx
Sponsor: HOOKIPA PHARMA
Enrolling Sites:
Sylvester
Title: A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
Eligibility Criteria - NCT04180215 *This information has been extracted from " www.clinicaltrials.gov"
RPL-001-16 - Rodriguez, Estelamari
-
Investigator:
Estelamari Rodriguez
Email
Coordinator: Yanel Diaz Caro
+1 (786) 5828551
IRB: 20180802
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bladder,Breast-Female,Colon,Melanoma, skin,Other Skin
Sponsor: REPLIMUNE
Enrolling Sites:
Sylvester
Title: RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"
20201368 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator:
IRB: 20201368
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Multiple
Sponsor: SCCC
Enrolling Sites:
Plantation
SylvesterTitle: ctDNA-Guided Sunitinib And Regorafenib Therapy for Gastrointestinal Stromal Tumor (GIST)
Eligibility Criteria - NCT05366816 *This information has been extracted from " www.clinicaltrials.gov"
20201373 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator:
IRB: 20201373
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Hodgkin Lymphoma,Lip, Oral Cavity and Pharynx,Lung,Melanoma, skin,Soft Tissue
Sponsor: Agenus
Enrolling Sites:
Sylvester
Title: A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Eligibility Criteria - NCT03860272 *This information has been extracted from " www.clinicaltrials.gov"
20211168 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator:
IRB: 20211168
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Colon,Esophagus,Small Intestine,Soft Tissue,Stomach
Sponsor: Theseus Pharmaceuticals
Enrolling Sites:
Sylvester
Title: A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti- Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
Eligibility Criteria - NCT05160168 *This information has been extracted from " www.clinicaltrials.gov"
20211225 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator: Ravipal Luthra
+1 (305) 2430933
IRB: 20211225
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Multiple
Sponsor: Cogent Biosciences
Enrolling Sites:
Sylvester
Title: (PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC GASTROINTESTINAL STROMAL TUMORS
Eligibility Criteria - NCT05208047 *This information has been extracted from " www.clinicaltrials.gov"
20220946 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator:
IRB: 20220946
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Bones and Joints
Sponsor: ADVENCHEN LABORATORIES
Enrolling Sites:
Sylvester
Title: An Open Label Post-Trial Access (PTA) of Catequentinib (AL3818, Anlotinib) Hydrochloride Mono or in Combination Therapies in Patients Who Have Completed an Advenchen Sponsored Oncology Study with AL3818 (A Compassionate Use Trial)
Eligibility Criteria - NCT05612191 *This information has been extracted from " www.clinicaltrials.gov"
20220980 - Trent Jonathan
-
Investigator:
Jonathan Trent
Email
Coordinator:
IRB: 20220980
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Multiple
Sponsor: IDRX
Enrolling Sites:
Sylvester
Title: A First-In-Human (FIH) Study Of Idrx-42 In Participants With Metastatic And/Or Unresectable Gastrointestinal Stromal Tumors (GIST)
Eligibility Criteria - NCT05489237 *This information has been extracted from " www.clinicaltrials.gov"